Stéphane Boissel has been appointed to succeed Damian Marron as chief executive officer of TxCell SA which has a clinical-stage immunotherapy product for the treatment of inflammatory bowel diseases. Mr Boissel was most recently CEO of Genclis SAS, a molecular diagnostics company. Before that, he was chief financial officer at Transgene SA and Innate Pharma SA. Mr Boissel worked for the investment banking group, Lazard, for eight years and studied management and finance at the University of Lyon in France. He received his MBA from the Chicago Booth Graduate Business School in the US.
TxCell has also promoted Miguel Forte to the job of chief operating officer from the position of senior vice president for clinical and regulatory affairs.
TxCell announced the appointments on 28 April 2015.
Copyright 2015 Evernow Publishing Ltd